BIOX

Bioceres Crop Solutions Corp

Add to Watchlist

Advanced Chart

4.270

+0.040(+0.950%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

4.440

Open

4.350

VWAP

4.21

Vol

107.94K

Mkt Cap

267.78M

Low

4.100

Amount

454.28K

EV/EBITDA(TTM)

11.41

Total Shares

60.59M

556.27M

EV/OCF(TTM)

P/S(TTM)

0.66

Bioceres Crop Solutions Corp. is a provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. Its segments include Seed and integrated products, Crop protection and Crop nutrition. Seed and integrated products segment focuses on the development and commercialization of seed technologies and products, including provision of seed technologies integrated with crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics. Crop protection segment includes the development, production and marketing of adjuvants and a range of pest control molecules and biocontrol products. Crop nutrition segment focuses on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers, including biofertilizers and micro-granulated fertilizers that optimize the productivity and yield of the crops.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

61.87M

-26.35%

-0.100

-171.94%

115.67M

-6.95%

0.115

-550.98%

105.00M

+12.54%

0.020

-123.28%

Estimates Revision

The market is revising Downward the revenue expectations for Bioceres Crop Solutions Corp. (BIOX) for FY2025, with the revenue forecasts being adjusted by -15.96% over the past three months. During the same period, the stock price has changed by -38.96%.

Revenue Estimates for FY2025

Revise Downward

-15.96%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-155.93%

In Past 3 Month

Stock Price

Go Down

-38.96%

In Past 3 Month

2 Analyst Rating

69.79% Upside

Wall Street analysts forecast BIOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOX is 7.25 USD with a low forecast of 6.50 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

69.79% Upside

Current: 4.270

Low

6.50

Averages

7.25

High

8.00

69.79% Upside

Current: 4.270

Low

6.50

Averages

7.25

High

8.00

Oppenheimer

Kristen Owen

Buy

Maintains

$8 → $7

2025-04-22

Reason

Oppenheimer

Kristen Owen

Price Target

$8 → $7

2025-04-22

Maintains

Buy

Reason

Oppenheimer lowered the firm's price target on Bioceres to $7 from $8 and keeps an Outperform rating on the shares. Amid tariff and macro uncertainty, agriculture has "proved a relatively resilient pocket of the market," the analyst tells investors in a research note. The firm says that while not immune to tariffs and retaliatory measures, ag's fundamental setup coming into 2025 remains intact. The potential for government subsidies helps dampen the economic impact on farmer customers, contends Oppenheimer.

Canaccord Genuity

Austin Moeller

Strong Buy

Maintains

$7 → $6.5

2025-02-13

Reason

Canaccord Genuity

Austin Moeller

Price Target

$7 → $6.5

2025-02-13

Maintains

Strong Buy

Reason

Canaccord analyst Austin Moeller lowered the firm's price target on Bioceres to $6.50 from $7 and keeps a Buy rating on the shares. The firm noted management announced its intent to pivot away from Bioceres' seed business to focus on trait development and leverage key partnerships to expand its footprint internationally.

Lake Street

Ben Klieve

Strong Buy

Maintains

$13 → $8

2025-02-07

Reason

Lake Street

Ben Klieve

Price Target

$13 → $8

2025-02-07

Maintains

Strong Buy

Reason

Canaccord Genuity

Austin Moeller

Strong Buy

Maintains

$9.5 → $7

2025-02-07

Reason

Canaccord Genuity

Austin Moeller

Price Target

$9.5 → $7

2025-02-07

Maintains

Strong Buy

Reason

Oppenheimer

Kristen Owen

Buy

Maintains

$13 → $12

2025-01-28

Reason

Oppenheimer

Kristen Owen

Price Target

$13 → $12

2025-01-28

Maintains

Buy

Reason

Canaccord Genuity

Austin Moeller

Strong Buy

Maintains

$10 → $9.5

2024-11-13

Reason

Canaccord Genuity

Austin Moeller

Price Target

$10 → $9.5

2024-11-13

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Bioceres to $9.50 from $10 and keeps a Buy rating on the shares. The firm said while the Q1 print confirmed our previous expectation that farmers in Latin America would take a bit longer to recover from El Nino drought trends, we believe that normalizing Argentinian rainfall suggests the weather headwinds are subsiding and could enable a Q2 recovery

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bioceres Crop Solutions Corp (BIOX.O) is 18.80, compared to its 5-year average forward P/E of 28.12. For a more detailed relative valuation and DCF analysis to assess Bioceres Crop Solutions Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

28.12

Current PE

18.80

Overvalued PE

49.97

Undervalued PE

6.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

9.89

Current EV/EBITDA

9.34

Overvalued EV/EBITDA

12.17

Undervalued EV/EBITDA

7.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.52

Current PS

0.66

Overvalued PS

1.97

Undervalued PS

1.07

Financials

Annual

Quarterly

FY2025Q2

YoY :

-23.87%

106.80M

Total Revenue

FY2025Q2

YoY :

-52.59%

7.40M

Operating Profit

FY2025Q2

YoY :

-51.55%

600.00K

Net Income after Tax

FY2025Q2

0.00

EPS - Diluted

FY2025Q1

YoY :

-166.50%

-2.79M

Free Cash Flow

FY2025Q2

YoY :

+15.09%

42.32

Gross Profit Margin - %

FY2025Q2

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q2

YoY :

-36.36%

0.56

Net Margin - %

FY2025Q2

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 352.23% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

421.9K

Volume

Months

6-9

0.0

Volume

Months

0-12

93.3K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BIOX News & Events

Events Timeline

2025-04-21 (ET)

2025-04-21

07:15:56

Moolec Science, Bioceres Group enter business combination agreement

2025-02-11 (ET)

2025-02-11

17:20:11

Bioceres reports Q2 adjusted EBITDA $15.4M vs. $24.1M last year

2025-02-11

17:20:11

Bioceres reports Q2 adjusted EBITDA $15.4M vs. $24.1M last year

News

4.5

03-25NASDAQ.COM

Tuesday's ETF Movers: ARGT, URA

4.5

03-18NASDAQ.COM

Tuesday's ETF Movers: COPX, ARGT

9.0

03-11Newsfilter

Bioceres Crop Solutions Announces EPA Registration of Rinotec Insecticide and Nematicide Platform, a Game-Changing Solution for Integrated Pest Management